- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
US Cuts Could Jeopardize Global Health Innovations, Says Report
Cuts to US global health and research programs for diseases such as AIDS, tuberculosis and malaria risk derailing the innovations crucial to fighting these diseases, according a new report by the Global Health Technologies Coalition.
Cuts to US global health and research programs for diseases such as AIDS, tuberculosis and malaria risk derailing the innovations crucial to fighting these diseases, according a new report by the Global Health Technologies Coalition.
The report asserts that without continued and consistent US investment in global health research - which has so far “helped deliver some of the greatest advances the field has ever seen” - the momentum needed to do drive these advances “over the finish line” will be compromised.
The report will be released at a congressional briefing at noon, Tuesday, February 26, at the Russell Senate Office Building, Washington, DC. An expert panel - including Dr Caroline Ryan, Director of Technical Leadership, Office of the Global AIDS Coordinator, Department of State, PEPFAR (President’s Emergency Plan for AIDS Relief) and Dr Alan Magill, Director of Malaria, Bill & Melinda Gates Foundation - will be speaking at the event.
For more information, contact Katy Lenard (klenard@burnesscommunications.com)
T: +1 301-280-5719
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
